APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (APCVZ), Thursday said it has received approval from the U.S. Food and Drug Administration, or FDA, to market Sumatriptan Succinate injection, USP, in two dosage strengths of 4 mg (base)/0.5 mL and 6 mg (base)/0.5 mL.
Sumatriptan Succinate injection, which is therapeutically equivalent to GlaxoSmithKline plc's (GSK) drug Imitrex, is a vascular headache suppressant indicated for the acute treatment of migraine attacks.
In February 2009, APP Pharma received approval for Sumatriptan Succinate for injection, USP packaged in single dose vials of 6 milligram/0.5 milliliter.
According to IMS Health data, 2008 sales of Sumatriptan Succinate injection in the US were nearly $241 million. Refills and syringe cartridges accounted for over $218 million.
APP Pharma was acquired by Fresenius Kabi Pharmaceuticals in September 2008, and has offices in Canada and manufacturing operations in Illinois, New York and Puerto Rico.
APCVZ closed Wednesday's regular trading at $0.53 per share on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.